ECM
CRNX icon

Everence Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Everence Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,805
Closed -$270K – 820
2025
Q4 		$270K Hold
5,805
– – 0.02% 639
2025
Q3 		$242K Buy
+5,805
New +$186K 0.01% 692

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Everence Capital Management's CRNX Position: Q1 2026 in Review

Everence Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 5,805 shares — an estimated $270K sold.

Everence Capital Management first reported a position in CRNX in Q3 2025 and held it in 2 quarters. The position peaked at $270K in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Everence Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Everence Capital Management sold 5,805 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $270K.
  • Everence Capital Management first reported a position in Crinetics Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Everence Capital Management's Crinetics Pharmaceuticals position peaked at $270K in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Everence Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.